Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.47
+0.29 (1.91%)
At close: Aug 14, 2026, 4:00 PM EDT
15.48
+0.01 (0.06%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $58.57M in the quarter ending June 30, 2026, with 13.84% growth. This brings the company's revenue in the last twelve months to $286.86M, up 18.76% year-over-year. In the year 2025, Aurinia Pharmaceuticals had annual revenue of $283.06M with 20.38% growth.
Revenue (ttm)
$286.86M
Revenue Growth
+18.76%
P/S Ratio
6.61
Revenue / Employee
$2,433,648
Employees
128
Market Cap
2.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.06M | 47.92M | 20.38% |
| Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
| Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
| Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
| Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
| Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
| Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
| Dec 31, 2018 | 463.00K | 45.00K | 10.77% |
| Dec 31, 2017 | 418.00K | 245.00K | 141.62% |
| Dec 31, 2016 | 173.00K | -1.00M | -85.29% |
| Dec 31, 2005 | 1.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| ADMA Biologics | 512.28M |
| Septerna | 98.88M |
| Agios Pharmaceuticals | 98.34M |
| Nanobiotix | 38.27M |
| Stoke Therapeutics | 27.59M |
| Generate Biomedicines | 26.48M |
| Taysha Gene Therapies | 5.49M |
AUPH News
- 7 days ago - Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital - TheFly
- 8 days ago - Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M - TheFly
- 8 days ago - Aurinia Pharmaceuticals reports Q2 EPS 28c, consensus 24c - TheFly
- 8 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - Business Wire
- 8 days ago - Aurinia Pharmaceuticals Earnings release: Q2 2026 - Filings
- 8 days ago - Aurinia Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Aurinia Pharmaceuticals announces initiation of PRESERVE study - TheFly
- 5 weeks ago - Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - Business Wire